Catalyst Event
Eli Lilly and Co (LLY) · Other
From Akros U.S. Large Cap 500 Index (AUL500)
3/19/2026, 12:00:00 AM
Eli Lilly announced positive topline results from the TRANSCEND-T2D-1 Phase 3 trial on March 19, 2026, showing its next-generation 'Triple-G' agonist, retatrutide, led to significant reductions in A1C and body weight.
Korean Translation
2026년 3월 19일, 차세대 'Triple-G' 작용제인 레타트루타이드가 제2형 당뇨병 성인 환자의 당화혈색소(A1C)와 체중을 유의미하게 감소시켰다는 TRANSCEND-T2D-1 3상 임상시험의 긍정적인 탑라인 결과를 발표함.
Related Recent Events
Hewlett Packard Enterprise Co (HPE) · Other
HPE Discover Las Vegas 2026, the company's flagship annual event, is scheduled to begin, running from June 15-18. Major announcements on AI, cloud, and networking are anticipated to drive market interest scheduled.
6/15/2026, 12:00:00 AM
Hewlett Packard Enterprise Co (HPE) · Earnings Release
Fiscal Q2 2026 earnings release is expected. The company guided for revenue between $9.6 billion and $10.0 billion and non-GAAP EPS between $0.51 and $0.55. High volatility is anticipated based on historical earnings reactions expected.
6/2/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
FDA PDUFA action date for the supplemental Biologics License Application (sBLA) for a subcutaneous formulation of LEQEMBI is May 24, 2026; Medium importance is estimated due to uncertain market reaction scheduled.
5/24/2026, 12:00:00 AM
Target Corp (TGT) · Earnings Release
Q1 2026 earnings release scheduled for 2026-05-20 scheduled.
5/20/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 2027 earnings release is scheduled for May 20, 2026; Medium importance is assigned as earnings typically drive 5-10% volatility, and analysts forecast an EPS of $1.74-$1.76 estimated.
5/20/2026, 12:00:00 AM
ONEOK Inc (OKE) · Other
2026 Annual Meeting of Shareholders, which is expected to have low impact as a standard meeting, is scheduled.
5/20/2026, 12:00:00 AM